June 1, 2023
APIM Therapeutics will be attending the ASCO Annual Congress to be held in Chicago, US between June 2-6.
APIM Therapeutics will be attending the ASCO Annual Congress to be held in Chicago, US between June 2-6.
APIM Therapeutics will be attending the ESMO Congress 2022 held in Paris, France between September 9-13.
APIM Therapeutics will be attending the 2021 ASCO Annual Meeting, Fri, Jun 4, 2021 – Tue, Jun 8, 2021.
APIM Therapeutics will be participating at the virtual Biopharma CxO Roundtable entitled: “Clinical trial acceleration — 500 days faster from start to finish” organized by McKinsey & Company and Hadean Ventures on February 16th, 2021. More information on the roundtable can be found here.
APIM Therapeutics will be participating at the Global Pharmaceutical and Biotechnology Conference, 9th - 11th November 2020.
APIM Therapeutics will be participating at the 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, 29th - 30th October 2020.
APIM Therapeutics will be participating at the BioEurope Spring Partnering meeting, in Vienna, Austria (March 25-27, 2019).
APIM Therapeutics will be participating at BioEurope Spring Partnering meeting, in Barcelona, Spain (March 20-22, 2017).
APIM Therapeutics will be participating at BioEurope Partnering meeting, in Cologne, Germany (November 7-9, 2016).
APIM Therapeutics will be participating at the Nordic Life Sciences Days conference in Stockholm (September 14-15, 2016). A presentation during the Biotechnology Track: R&D Services/Therapeutics & Diagnostics/Others will be given on Sept. 14, 17.15.
APIM Therapeutics will be participating at the BIO 2016 International Convention in San Francisco (June 6-9, 2016).
APIM Therapeutics will be participating at the BioTrinity 2016 and BioEquity 2016 partnering meetings held on April 25-27 and May 10-11, 2016 in London and Copenhagen, respectively.
APIM Therapeutics's CSO and NTNU Professor Marit Otterlei presents latest results obtained with ATX-101 in preclinical efficacy models in the 14th International Congress on Targeted Anticancer Therapies, 21-23 March, 2016, Washington, USA. A copy of the poster presented is available here.
APIM Therapeutics will be participating at the 9th Annual European Life Science CEO Forum & Exhibition held on 15th-16th March 2016 in Zurich.
APIM Therapeutics will be participating at the 10th Swiss-Scandinavian Bio-Business Seminar held on February 10, 2016 at the SIX Stock Exchange building in Zurich.
APIM Therapeutics's CEO, Kostas Alevizopoulos, will be presenting the company's latest development plans in the BioTrinity Investor Conference in London (May 11-13, 2015).
APIM Therapeutics has been selected to present at the 10th European Partnering and Investment Conference (EPIC) held in London, UK in June 6, 2013. The conference brings together 250 - 300 delegates from the pharma, biotech, investor, CRO and service sectors.
APIM Therapeutics will be presenting an abstract entitled "Increased efficacy of intravesical chemotherapy in an orthotopic rat bladder cancer model by targeting PCNA with the novel synthetic peptide drug ATX-101" at the Annual Meeting of the American Association of Urology held in San Diego in May 4-8, 2013.
APIM Therapeutics will be presenting an abstract entitled "Targeting DNA repair mechanisms increases efficiency of intravesical chemotherapy in an orthotopic rat bladder cancer model" at the 28th Annual European Urology Association Meeting held in Milan in March 15-19, 2013.
APIM Therapeutics has been selected to present at the 6th ANNUAL EUROPEAN LIFE SCIENCE CEO FORUM PARTNERING & INVESTING in Biotech & Pharma Industry. The conference, which takes place in March 5-6, 2013 in Zurich, brings together together an exciting cross-section of venture-funded and small-cap companies with leading investors, pharmas, and scientific thought leaders.